TITLE

HARBOR study examines high-dose ranibizumab for neovascular AMD

AUTHOR(S)
Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney
PUB. DATE
February 2011
SOURCE
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on the preliminary information regarding the HARBOR study, which compares the 0.5 milligrams (mg) of Lucentis and 2 mg of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD), presented by doctor Allen C. Ho.
ACCESSION #
86439050

 

Related Articles

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. Young Gun Park; Hyun Wook Rhu; Seungbum Kang; Young Jung Roh // Journal of Ophthalmology;2012, p1 

    Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all...

  • Treat-and-extend therapy a popular, cost-effective approach to treating neovascular AMD.  // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p16 

    The article focuses on the use of treat-and-extend therapy as a cost-effective and popular treatment option for neovascular age-related macular degeneration (AMD).

  • CATT researcher offers perspective on interpreting trial results. Correa, Mark; Hasson, Matt; Mullin, David W.; Pagnani, Michelle // Ocular Surgery News;2/25/2012, Vol. 30 Issue 4, special section p10 

    The article reports on how ophthalmologists consider data derived from the Comparison of Age-Related Macular Degeneration Traetment Trials that compared ranibizumab and bevacizumab.

  • CATT provides reassuring data on anti-VEGF use, but some Questions remain.  // Ocular Surgery News;1/25/2012, Vol. 30 Issue 2, Special section p11 

    The article reports that the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) offers reassuring data on anti-vascular endothelial growth factor (VEGF) use but another year of investigation in necessary to draw more definitive conclusions according to physician Neil M....

  • Anti-VEGF drugs in the prevention of blindness. Yorston, David // Community Eye Health Journal;2014, Vol. 27 Issue 87, p44 

    The article discusses the use of anti-vascular endothelial growth factor (VEGF) drugs to prevent blindness. Topics discussed include the disorders of blood vessels in the retina, the role of over-production of VEGF protein in blindness, a summary of the effects of VEGF, the importance of giving...

  • Differences in 1-year anatomical outcomes for CATT categorized as subtle. Pagnani, Michelle; Charles, Steve // Ocular Surgery News;9/25/2011, Vol. 29 Issue 18, p22 

    The article reports on the results of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) involving retinal fluids, presented by researcher Glenn J. Jaffe at the 2011 Meeting of the American Society of Retina Specialists (ASRS) in Boston, Massachusetts.

  • Certification figures and their accuracy. Quartilho, A; Zekite, A; Xing, W; Loutfi, M; Bunce, C; Wormald, R // Eye;Nov2015, Vol. 29 Issue 11, p1516 

    A letter to the editor is presented in response to a paper by M. Buckle et al where they assert that the limitations of certification data to estimate the true incidence of blindness and visual impairment have been demonstrated repeatedly.

  • The Use of Anti-VEGF Agents Beyond AMD. Wiegand, Torsten W.; Cleary, Tina S.; Heier, Jeffrey S. // Review of Ophthalmology;Apr2007 Part 1 of 2, Vol. 14 Issue 4, p105 

    The article discusses the use of anti-vascular endothelial growth factor (VEGF) agents in treating not just age-related macular degeneration (AMD) but other eye diseases as well. Angiogenesis and vascular permeability plays an important roles in many ocular diseases. VEGF is a homodimeric...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics